论文已发表
提 交 论 文
注册即可获取Ebpay生命的最新动态
注 册
IF 收录期刊
Authors Feng XQ, Zhu LL, Zhou Q
Received 3 April 2017
Accepted for publication 2 May 2017
Published 24 May 2017 Volume 2017:10 Pages 1225—1239
DOI http://doi.org/10.2147/JPR.S138698
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Michael Schatman
Background: Multimorbidity results in complex polypharmacy which may bear a risk of
drug interactions. A better understanding of opioid analgesics combination
therapy used for pain management could help warrant medication safety,
efficacy, and economic relevance. Until now there has been no review
summarizing the opioid analgesics-related pharmacokinetic drug interactions
from the perspective of evidence based on randomized controlled trials (RCTs).
Method: A literature search was performed using PubMed,
MEDLINE, and the Cochrane Library, using a PRISMA flowchart.
Results: Fifty-two RCTs were included for data interpretation.
Forty-two RCTs (80.8%) were conducted in healthy volunteers, whereas 10 RCTs
(19.2%) enrolled true patients. None of the opioid–drug/herb pairs was listed
as contraindications of opioids involved in this review. Circumstances in which
opioid is comedicated as a precipitant drug include morphine–P2Y12 inhibitors,
morphine–gabapentin, and methadone–zidovudine. Circumstances in which opioid is
comedicated as an object drug include rifampin–opioids (morphine, tramadol,
oxycodone, methadone), quinidine–opioids (morphine, fentanyl, oxycodone,
codeine, dihydrocodeine, methadone), antimycotics–opioids (buprenorphine,
fentanyl, morphine, oxycodone, methadone, tilidine, tramadol), protease
inhibitors–opioids (ritonavir, ritonavir/lopinavir–oxycodone,
ritonavir–fentanyl, ritonavir–tilidine), grapefruit juice–opioids (oxycodone,
fentanyl, methadone), antidepressants–opioids (paroxetine–tramadol,
paroxetine–hydrocodone, paroxetine–oxycodone, escitalopram–tramadol),
metoclopramide–morphine, amantadine–morphine, sumatriptan–butorphanol nasal
sprays, ticlopidine–tramadol, St John’s wort–oxycodone,
macrolides/ketolides–oxycodone, and levomepromazine–codeine. RCTs investigating
the same combination, almost unanimously, drew consistent conclusions, except
two RCTs on amantadine–intravenous morphine combination where a different
amantadine dose was used and two RCTs on morphine–ticagrelor combination where
healthy volunteers and true patients were enrolled, respectively. RCTs
investigating in true patients may reflect a realistic clinical scenario and
overcome the limitation of RCTs performed in healthy volunteers under
standardized conditions. Further research opportunities are also presented in
this review.
Conclusion: Effective and safe
combination therapy of opioids can be achieved by promoting the awareness of
potential changes in therapeutic efficacy and toxicities, prescribing
alternatives or changing administration strategy, tailoring dose, reviewing the
appropriateness of orders, and paying attention to medication monitoring.
Keywords: adverse drug reaction, clinical
efficacy, combination therapy, drug-drug interactions, drug metabolism, drug
transporter, pain management, pharmacokinetics, polypharmacy